A combination of the probiotic and prebiotic product can prevent the germination of Clostridium difficile spores and infection

Anaerobe

Volumn 47, Issue , 2017, Pages 94-103

  Ratsep M ^a,b   Koljalg S ^a   Sepp, E ^a   Smidt, I ^a   Truusalu, K ^a   Songisepp, E ^b   Stsepetova, J ^a   Naaber, P ^a   Mikelsaar, R H ^a   Mikelsaar, M ^a,b  

^a UNIVERSITY OF TARTU   (Estonia)

^b Bio Competence Centre of Healthy Dairy Products LLC   (Estonia)

Author keywords

Antibiotic susceptibility; Clostridium difficile; Lactobacillus plantarum inducia; Prevention; Spores; Xylitol

Indexed keywords

ANTIINFECTIVE AGENT; PREBIOTIC AGENT; PROBIOTIC AGENT; XYLITOL;

ANIMAL; ANTIBIOSIS; BACTERIAL SPORE; CLOSTRIDIUM INFECTION; DISEASE MODEL; DRUG EFFECT; ESTONIA; GROWTH, DEVELOPMENT AND AGING; HUMAN; ISOLATION AND PURIFICATION; LACTOBACILLUS PLANTARUM; MALE; MESOCRICETUS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; NORWAY; PEPTOCLOSTRIDIUM DIFFICILE; PHYSIOLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBIOSIS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DISEASE MODELS, ANIMAL; ESTONIA; HUMANS; LACTOBACILLUS PLANTARUM; MALE; MESOCRICETUS; MICROBIAL SENSITIVITY TESTS; NORWAY; PREBIOTICS; PROBIOTICS; SPORES, BACTERIAL; XYLITOL;

EID: 85019055660     PISSN: 10759964     EISSN: 10958274     Source Type: Journal    
DOI: 10.1016/j.anaerobe.2017.03.019     Document Type: Article

References (58)

1. [1] Hall, I.C., O'Toole, E., Intestinal flora in new-born infants: with a description of a new pathogenic anaerobe, Bacillus difficiles. Am. J. Dis. Child. 49 (1935), 390–402.
2. [2] Bartlett, J.G., et al. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N. Engl. J. Med. 298:10 (1978), 531–534.
3. [3] Cohen, S.H., et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect. Control Hosp. Epidemiol. 31:5 (2010), 431–455.
4. [4] Goudarzi, M., et al. Clostridium difficile infection: epidemiology, pathogenesis, risk factors, and therapeutic options. Sci. (Cairo), 2014, 2014, 916826.
5. [5] Bauer, M.P., et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 377:9759 (2011), 63–73.
6. [6] Burke, K.E., Lamont, J.T., Clostridium difficile infection: a worldwide disease. Gut Liver 8:1 (2014), 1–6.
7. [7] Depestel, D.D., Aronoff, D.M., Epidemiology of Clostridium difficile infection. J. Pharm. Pract. 26:5 (2013), 464–475.
8. [8] Kuipers, E.J., Surawicz, C.M., Clostridium difficile infection. Lancet 371:9623 (2008), 1486–1488.
9. [9] Eyre, D.W., et al. Predictors of first recurrence of Clostridium difficile infection: implications for initial management. Clin. Infect. Dis. 55:Suppl 2 (2012), S77–S87.
10. [10] Bagdasarian, N., Rao, K., Malani, P.N., Diagnosis and treatment of Clostridium difficile in adults: a systematic review. JAMA 313:4 (2015), 398–408.
11. [11] Britton, R.A., Young, V.B., Interaction between the intestinal microbiota and host in Clostridium difficile colonization resistance. Trends Microbiol. 20:7 (2012), 313–319.
12. [12] Rodriguez-Palacios, A., Lejeune, J.T., Moist-heat resistance, spore aging, and superdormancy in Clostridium difficile. Appl. Environ. Microbiol. 77:9 (2011), 3085–3091.
13. [13] Burns, D.A., Minton, N.P., Sporulation studies in Clostridium difficile. J. Microbiol. Methods 87:2 (2011), 133–138.
14. [14] Schenck, L.P., Beck, P.L., MacDonald, J.A., Gastrointestinal dysbiosis and the use of fecal microbial transplantation in Clostridium difficile infection. World J. Gastrointest. Pathophysiol. 6:4 (2015), 169–180.
15. [15] Hickson, M., Probiotics in the prevention of antibiotic-associated diarrhoea and Clostridium difficile infection. Ther. Adv. Gastroenterol. 4:3 (2011), 185–197.
16. [16] Rohlke, F., Stollman, N., Fecal microbiota transplantation in relapsing Clostridium difficile infection. Ther. Adv. Gastroenterol. 5:6 (2012), 403–420.
17. [17] Brown, W.R., Fecal microbiota transplantation in treating Clostridium difficile infection. J. Dig. Dis. 15:8 (2014), 405–408.
18. [18] Hawrelak, J.A., Myers, S.P., The causes of intestinal dysbiosis: a review. Altern. Med. Rev. 9:2 (2004), 180–197.
19. [19] Naaber, P., et al. Colonization of infants and hospitalized patients with Clostridium difficile and lactobacilli. Clin. Infect. Dis. 25:Suppl 2 (1997), S189–S190.
20. [20] Bartosch, S., et al. Characterization of bacterial communities in feces from healthy elderly volunteers and hospitalized elderly patients by using real-time PCR and effects of antibiotic treatment on the fecal microbiota. Appl. Environ. Microbiol. 70:6 (2004), 3575–3581.
21. [21] Beausoleil, M., et al. Effect of a fermented milk combining Lactobacillus acidophilus Cl1285 and Lactobacillus casei in the prevention of antibiotic-associated diarrhea: a randomized, double-blind, placebo-controlled trial. Can. J. Gastroenterol. 21:11 (2007), 732–736.
22. [22] Goldin, B.R., Gorbach, S.L., Clinical indications for probiotics: an overview. Clin. Infect. Dis. 46:Suppl 2 (2008), S96–S100 discussion S144–51.
23. [23] Goldenberg, J.Z., et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst. Rev.(5), 2013 p. CD006095.
24. [24] Tejero-Sarinena, S., et al. Antipathogenic activity of probiotics against Salmonella Typhimurium and Clostridium difficile in anaerobic batch culture systems: is it due to synergies in probiotic mixtures or the specificity of single strains?. Anaerobe 24 (2013), 60–65.
25. [25] Mikelsaar, M., et al. Biodiversity of intestinal lactic acid bacteria in the healthy population. Adv. Exp. Med. Biol., 932, 2016.
26. [26] Talbot, J.M., Fisher, K.D., The need for special foods and sugar substitutes by individuals with diabetes mellitus. Diabetes Care 1:4 (1978), 231–240.
27. [27] Naaber, P., Mikelsaar, M., Interactions between Lactobacilli and antibiotic-associated diarrhea. Adv. Appl. Microbiol. 54 (2004), 231–260.
28. [28] Mikelsaar, M., et al., Lactobacillus plantarum Inducia DSM 21379 as enhancer of cellular immunity, hypocholesterolemic and anti-oxidative agent and antimicrobial agent against Clostridium difficile. USA patent application US15/132.286, filed 19.04.2016, patent owner: Bio-Competence Centre of Healthy Dairy Products LLC. 2016.
29. [29] Mikelsaar, M., et al., Isolated Lactobacillus plantarum strain Inducia DSM 21379 as probiotic that enhances natural immunity and food products and medicinal preparations comprising it. European Patent EP2288360, granted 14.12.2011 Patent owner: Bio-Competence Centre of Healthy Dairy Products. 2011.
30. [30] Yakob, L., et al. Mechanisms of hypervirulent Clostridium difficile ribotype 027 displacement of endemic strains: an epidemiological model. Sci. Rep., 5, 2015, 12666.
31. [31] Naaber, P., et al. Quantification of Clostridium difficile in antibiotic-associated-diarrhea patients. J. Clin. Microbiol. 49:10 (2011), 3656–3658.
32. [32] Sepp, E., et al. Intestinal lactoflora in Estonian and Norwegian patients with antibiotic associated diarrhea. Anaerobe 17:6 (2011), 407–409.
33. [33] Ratsep, M., et al. Effect of lactobacillus plantarum strains on clinical isolates of Clostridium difficile in vitro. J. Prob Health, 2(119), 2014.
34. [34] Baines, S.D., Freeman, J., Wilcox, M.H., Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model. J. Antimicrob. Chemother. 55:6 (2005), 974–982.
35. [35] Annuk, H., et al. Characterization of intestinal lactobacilli as putative probiotic candidates. J. Appl. Microbiol. 94:3 (2003), 403–412.
36. [36] Mikelsaar, M., Annuk, H., Stsepetova, J., Intestinal lactobacilli of estonian and Swedish children. Microb. Ecol. Health Dis. 14 (2002), 75–80.
37. [37] Kondepudi, K.K., et al. Prebiotic-non-digestible oligosaccharides preference of probiotic bifidobacteria and antimicrobial activity against Clostridium difficile. Anaerobe 18:5 (2012), 489–497.
38. [38] Douce, G., Goulding, D., Refinement of the hamster model of Clostridium difficile disease. Methods Mol. Biol. 646 (2010), 215–227.
39. [39] Sambol, S.P., et al. Infection of hamsters with epidemiologically important strains of Clostridium difficile. J. Infect. Dis. 183:12 (2001), 1760–1766.
40. [40] Merrigan, M., et al. Susceptibility of hamsters to human pathogenic Clostridium difficile strain B1 following clindamycin, ampicillin or ceftriaxone administration. Anaerobe 9:2 (2003), 91–95.
41. [41] Best, E.L., Freeman, J., Wilcox, M.H., Models for the study of Clostridium difficile infection. Gut Microbes 3:2 (2012), 145–167.
42. [42] Naaber, P., et al. Bacterial translocation, intestinal microflora and morphological changes of intestinal mucosa in experimental models of Clostridium difficile infection. J. Med. Microbiol. 47:7 (1998), 591–598.
43. [43] Heilig, H.G., et al. Molecular diversity of Lactobacillus spp. and other lactic acid bacteria in the human intestine as determined by specific amplification of 16S ribosomal DNA. Appl. Environ. Microbiol. 68:1 (2002), 114–123.
44. [44] van den Berg, R.J., et al. Rapid diagnosis of toxinogenic Clostridium difficile in faecal samples with internally controlled real-time PCR. Clin. Microbiol. Infect. 12:2 (2006), 184–186.
45. [45] Surawicz, C.M., et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am. J. Gastroenterol. 108:4 (2013), 478–498 quiz 499.
46. [46] Hammarstrom, S., et al. Autoantibodies to colon in germfree rats monocontaminated with Clostridium difficile. J. Exp. Med. 129:4 (1969), 747–756.
47. [47] Koll, P., et al. Screening and evaluation of human intestinal lactobacilli for the development of novel gastrointestinal probiotics. Curr. Microbiol. 61:6 (2010), 560–566.
48. [48] Mikelsaar, M., Human microbial ecology: lactobacilli, probiotics, selective decontamination. Anaerobe 17:6 (2011), 463–467.
49. [49] Chilton, C.H., et al. Co-amoxiclav induces proliferation and cytotoxin production of Clostridium difficile ribotype 027 in a human gut model. J. Antimicrob. Chemother. 67:4 (2012), 951–954.
50. [50] Andersen, K.K., et al. Neutralization of Clostridium difficile toxin B mediated by engineered lactobacilli that produce single-domain antibodies. Infect. Immun. 84:2 (2016), 395–406.
51. [51] Dubberke, E.R., et al. Prevalence of Clostridium difficile environmental contamination and strain variability in multiple health care facilities. Am. J. Infect. Control 35:5 (2007), 315–318.
52. [52] Spinler, J.K., et al. Administration of probiotic kefir to mice with Clostridium difficile infection exacerbates disease. Anaerobe 40 (2016), 54–57.
53. [53] Badet, C., et al. Adaptation of salivary Lactobacillus strains to xylitol. Arch. Oral Biol. 49:2 (2004), 161–164.
54. [54] McFarland, L.V., Diarrhoea associated with antibiotic use. BMJ 335:7610 (2007), 54–55.
55. [55] Hamalainen, M.M., Makinen, K.K., Peroral xylitol increases the concentration levels of tissue iron in the rat. Br. J. Nutr. 50:1 (1983), 109–112.
56. [56] Ammons, M.C., et al. Combined treatment of Pseudomonas aeruginosa biofilm with lactoferrin and xylitol inhibits the ability of bacteria to respond to damage resulting from lactoferrin iron chelation. Int. J. Antimicrob. Agents 37:4 (2011), 316–323.
57. [57] Eisendle, M., et al. The intracellular siderophore ferricrocin is involved in iron storage, oxidative-stress resistance, germination, and sexual development in Aspergillus nidulans. Eukaryot. Cell 5:10 (2006), 1596–1603.
58. [58] Chilton, C.H., et al. Potential of lactoferrin to prevent antibiotic-induced Clostridium difficile infection. J. Antimicrob. Chemother. 71:4 (2016), 975–985.